PD-L1 expression was observed in serial biopsy samples in a phase 1 trial of nivolumab in combination with external beam radiation therapy and brachytherapy in patients with grade 5 prostate cancer and increased immune infiltration. Here, CD274 is linked to prostate carcinoma.